DRKS00014369招募中不适用
Prospective, open-label, multicentre, non-randomized, non-interventional, exploratory, comparative, uncontrolled Post Market Clinical Follow-Up Study of the Modular Revision Support (MRS)-Titan® Comfort - 2015-01-MRS-C
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one(—)
- 性别
- All
入选标准
- •Congenital or acquired hip joint defects
- •Arthrosis (degenerative, rheumatic)
- •Joint replacement (revision) already carried out and worn or in case of failed surgery
- •Defect of the geometric rotation center
- •Defects or malfunctions of the hip joint
- •Post-traumatic arthritis
- •Severe deformities (e.g. osteomyelitis)
排除标准
- •Obesity or overweight of the patient
- •Acute or chronic infections near the implantation
- •All cases in which a stable anchoring of the implant cannot be achieved
- •Diseases that impair bone growth such as cancer, renal dialysis, osteopenia, etc.
- •Sensitivity to foreign matter in the implant materials
- •Bone tumors in the area of the implant anchoring
- •Illnesses which can be treated without using a hip implant
- •Lack of patient cooperation
- •Abuse of medication, drug abuse, alcoholism or mental disease
- •Pregnancy
- •Serious damage to the bone structures, which might endanger stable implantation of the implant components (at least 1 mandrel screw)
- •Systemic diseases and metabolic disorders
- •Overload of the hip implant to be expected
- •In justified cases in which, despite one of the contra-indications described above, an implantation is considered to be medically necessary, the following must be observed:
- •The load capability of the material used in the device and for the fixation is limited.
- •Contra-indications must be reduced as far as possible.
- •Patients younger than 18 years
- •Participate in another clinical trial and receive / use experimental or unauthorized medicines or medical devices.
- •Existing disease of the other (unscheduled) hip with planned (surgical) intervention within the next 12 months.
- •Patients who can be put under pressure to volunteer.
研究者
相似试验
进行中(未招募)
不适用
Prospective, open-label, multicenter, non-randomized investigation on percutaneous patent foramen ovale (PFO) closure using the Occlutech PFO Occluder to prevent recurrence of stroke in patients with cryptogenic stroke and high risk PFOTHE PROOF STUDY – Occ2019_01 –Q24Other congenital malformations of heartDRKS00025198Occlutech International AB Landskronavägen 2574
已完成
不适用
PORTRAIT studyHypertgemiaD050171JPRN-jRCTs041200011Sumida Yoshio80
已完成
2 期
A open label, active control, phase 2 clinical study to evaluate immunogenicity, safety and tolerability of single heterologous booster dose of Protein Subunit Vaccine against SARS-CoV-2 Virus.CTRI/2023/09/057398Reliance Life Sciences Pvt Ltd RLS200
尚未招募
2 期
Prospective, multi-center, randomized, open label, active controlled, seamless phase 2/phase3 clinical study to evaluate immunogenicity, safety and tolerability of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences Pvt Ltd. against SARS-CoV-2 Virus) and Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) administered as primary vaccination.SARS-CoV-2PACTR202307772264605RELIANCE LIFE SCIENCE1,550
尚未招募
不适用
Study to compare the safety, tolerability and effectiveness of topical Minoxidil 5% solution in Indian male patients with mild to moderate pattern hair lossCTRI/2021/09/036777Hairrevive Centre for Hair Restoration Skin Rejuvenation
